H. Weber

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
H N Weber, H Weber, H. Weber, Holger Weber
Publication record
62 papers · 2,715 citations · H-index 22

PAPERS

Abstract 4148: Immunophenotyping of responses to immunotherapy in syngeneic tumor models using multiplex immunofluorescence compared to multiparametric flow cytometry
20230 citationsauthor #4
Abstract 4419: Use of luciferase-labeled target cells to explore immune cell killing in high throughput format in 2D and 3D co-cultures
20230 citationsauthor #7
Abstract 671: Exploiting macrophage differentiation and plasticity as an immunomodulating strategy
20230 citationsauthor #4
Abstract 5194: Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics
20230 citationsauthor #5
Abstract 33: Humanized MOLM-13 AML model as a versatile tool to study immune-activating agents
20230 citationsauthor #4
Abstract 1621: Comparison and consequences of different implantation techniques on the orthotopic growth of syngeneic Hepa1-6 liver cancer cells
20220 citationsauthor #6
Abstract 2318: Real-time quantitative PCR based analysis of transcriptional effects of CDK8/Cyclin C inhibitors
20221 citationsauthor #8
Abstract 629: Benefit of using a spectral flow analyzer for the analysis of immune cell populations in tumors
20221 citationsauthor #4
Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
20209 citationsauthor #6
Abstract 341: Synergy of FLT3 inhibitors and a small molecule inhibitor of LIM kinase1/2 in FLT3-ITD positive acute myeloblastic leukemia (AML)
20190 citationsauthor #7
Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches
20191 citationsauthor #6
Targeting hormone refractory prostate cancer by in vivo selected DNA libraries in an orthotopic xenograft mouse model
201916 citationsauthor #4
Prevention of tumor ulceration in mice – Mammary fat pad injection of tumor cells
20190 citationsauthor #8
Mouse-Derived Isograft (MDI) In Vivo Tumor Models I. Spontaneous sMDI Models: Characterization and Cancer Therapeutic Approaches
20195 citationsauthor #6
Abstract 495: All-in-one flow cytometry staining panel for immune-cell profiling in syngeneic tumor models
20190 citationsauthor #1
Abstract A012: Mammary fat pad injections: An alternative implantation method for syngeneic tumor models
20190 citationsauthor #8
Abstract A014: Evaluation of the hollow fiber model as a highly predictive in vivo testing system for the selection of xenograft tumor models in cancer drug discovery
20181 citationsauthor #2
Abstract 1156: New spontaneous and carcinogen-induced mouse-derived isograft (MDI) tumor models for immune therapeutic approaches
20180 citationsauthor #6
Abstract 5683: Value of new spontaneous and carcinogen-induced mouse-derived isograft (MDI) tumor models for drug development of novel immune therapeutic approaches
20180 citationsauthor #5
Abstract 3216: Anti-PD-1, Anti-PD-L1 and Anti-CTLA-4 checkpoint inhibitor treatment leads to different responses in syngeneic tumor models
20160 citationsauthor #4
Abstract 5010: A versatile tool to study immune checkpoint therapeutics: Syngenic tumor mouse models in vivo
20150 citationsauthor #7
Abstract B139: Determination of the plasma inhibitory activity of drugs using cellular kinase assays
20150 citationsauthor #2
Abstract A16: Boosting of in vivo hollow fiber assay by using luciferase-labeled tumor cell lines
20150 citationsauthor #6
Endothelial cell spheroids as a versatile tool to study angiogenesis in vitro
2015182 citationsauthor #5
Abstract 3377: Co-spheroid analysis reveals attenuating effect of HS27A stroma cells on DLD1 colon carcinoma susceptibility to MEK kinase inhibitor trametinib
20150 citationsauthor #4
Abstract 2026: Analysis of the impact of compounds derived from marine organisms on 3D co-spheroids generated from multiple myeloma cells and stromal cell types
20140 citationsauthor #2
Cell Lines Expressing Recombinant Transmembrane Domain–Activated Receptor Kinases as Tools for Drug Discovery
20143 citationsauthor #1
Abstract C109: Discovery of new natural anti-tumoral compounds using a parallel target- and phenotypic-driven screening approach.
20130 citationsauthor #2
Abstract 1554: Inducible B-Raf and c-Src models as tools for drug development.
20130 citationsauthor #6
173 Analysis of Cellular Kinase Activity of Resistance-related EGFR Mutants Using Transmembrane-Domain (TMD) Activated Kinase Variants
20120 citationsauthor #1
Abstract 5681: A high throughput soft agar assay on a panel of 60 tumor cell lines to study compounds for potential anti-oncogenic properties
20120 citationsauthor #1
The Antiangiogenic and Antitumoral Activity of Titanocene Y* In Vivo
201114 citationsauthor #7
Differential Endothelial Transcriptomics Identifies Semaphorin 3G as a Vascular Class 3 Semaphorin
201174 citationsauthor #2
Gamma-Secretase Inhibitor Treatment Promotes VEGF-A-Driven Blood Vessel Growth and Vascular Leakage but Disrupts Neovascular Perfusion
201141 citationsauthor #5
Abstract 5434: Functional screening for impact on cancer hallmarks migration, transformation and angiogenesis identifies potential new drug leads isolated from marine organisms
20110 citationsauthor #2
Abstract A141: Analysis of cellular kinase activity of resistance-related MET mutants using transmembrane-domain (TMD) activated kinase variants.
20110 citationsauthor #1
Antitumor activity of vanadocene Y and its selenocyanate derivative in xenografted caki-1 tumors in mice
201028 citationsauthor #8
Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
201057 citationsauthor #6
The Potency of Refined Mouse Models: Implications for Clinical Trials
20102 citationsauthor #5
Spheroid-based human endothelial cell microvessel formation in vivo
2009141 citationsauthor #5
Additive/synergistic efficacy of zoledronic acid and LBH589 in the spheroid-based cellular angiogenesis assay.
20090 citationsauthor #2
Increased expression of ALCAM/CD166 in pancreatic cancer is an independent prognostic marker for poor survival and early tumour relapse
2009109 citationsauthor #2
Combination of reverse and chemical genetic screens reveals angiogenesis inhibitors and targets.
200949 citationsauthor #14
Analyses of Titanocenes in the spheroid-based cellular angiogenesis assay.
200832 citationsauthor #1
In vitro and in vivo evaluation of doxorubicin conjugates with the divalent peptide E-[c(RGDfK)2] that targets integrin alphavbeta3.
200865 citationsauthor #4
Spheroid-based engineering of a human vasculature in mice
2008208 citationsauthor #3
Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
200822 citationsauthor #7
The BTB-Kelch Protein KLEIP Controls Endothelial Migration and Sprouting Angiogenesis
200733 citationsauthor #5
Extracellular Matrix–Bound Angiopoietin-Like 4 Inhibits Endothelial Cell Adhesion, Migration, and Sprouting and Alters Actin Cytoskeleton
2006196 citationsauthor #7
Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes.
200658 citationsauthor #3
The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms.
2006275 citationsauthor #6
Vascular endothelial growth factor (VEGF‐A) expression in human mesenchymal stem cells: Autocrine and paracrine role on osteoblastic and endothelial differentiation
2005336 citationsauthor #5
Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR).
200536 citationsauthor #2
Corrigendum to “Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR)” [Journal of Immunological Methods 300 (2005) 146–159]
20051 citationsauthor #2
Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule.
2005256 citationsauthor #2
Bi-directional cell contact-dependent regulation of gene expression between endothelial cells and osteoblasts in a three-dimensional spheroidal coculture model.
2004108 citationsauthor #3
Modulation of In Vitro Angiogenesis in a Three-Dimensional Spheroidal Coculture Model for Bone Tissue Engineering
2004174 citationsauthor #3
Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development
1998133 citationsauthor #3
Ex vivo activated memory T-lymphocytes as adoptive cellular therapy of human renal cell tumour targets with potentiation by cis-diamminedichloroplatinum(II).
19954 citationsauthor #5
Therapy of malignant brain tumors: comparison of the in vitro activities of vidarabin‐monophosphate, BCNU and 5‐fluorouracil
19877 citationsauthor #2
An In Vitro Comparative Study of BCNU, VM 26, 5-FU and Ara-A5’P in Treatment of Primary and Secondary CNS-Neoplasms; Potential Clinical Relevance and Clinical Correlations
19872 citationsauthor #3
Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.
198738 citationsauthor #3

TIMELINE

1987 47 citations

1995 4 citations

1998 133 citations

2004 282 citations

2005 629 citations

2006 529 citations

2007 33 citations

2008 327 citations

2009 299 citations

2010 87 citations

2011 129 citations

2012 0 citations

2013 0 citations

2014 3 citations

2015 182 citations

2016 0 citations

2018 1 citations

2019 22 citations

2020 9 citations

2022 2 citations

2023 0 citations

COAUTHOR MAP

CONCEPT FOOTPRINT